Cargando…
Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib
In the past few years, a better understanding of the genomic alterations in lung cancer has facilitated a targeted therapy. Lung adenocarcinomas with epidermal growth factor receptor mutations have a good response to tyrosine kinase inhibitors (TKIs). Osimertinib is a third-generation TKI approved b...
Autores principales: | González, Iván, Chatterjee, Deyali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657992/ https://www.ncbi.nlm.nih.gov/pubmed/31616716 http://dx.doi.org/10.14309/crj.0000000000000011 |
Ejemplares similares
-
Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022) -
Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020) -
A Case of Drug-Induced Liver Injury Secondary to Natalizumab
por: Santoiemma, Phillip P., et al.
Publicado: (2020) -
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017) -
Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)